CORONAVIRUS

Pfizer says COVID-19 pill cut hospital, death risk by 90%

Nov 5, 2021, 5:23 AM | Updated: 5:36 am
FILE PHOTO (Photo by Dan Kitwood - WPA Pool/Getty Images)...
FILE PHOTO (Photo by Dan Kitwood - WPA Pool/Getty Images)
(Photo by Dan Kitwood - WPA Pool/Getty Images)

WASHINGTON (AP) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.

Currently all COVID-19 treatments used in the U.S. require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.

Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.

Researchers worldwide have been racing to find a pill against COVID-19 that can be taken at home to ease symptoms, speed recovery and reduce the crushing burden on hospitals and doctors.

Pfizer released preliminary results Friday of its study of 775 adults. Patients taking the company’s drug along with another antiviral had an 89% reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than 1% of patients taking the drug needed to be hospitalized and no one died. In the comparison group, 7% were hospitalized and there were seven deaths.

“We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.

Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalization due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days.

Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20%.

An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit. The data have not yet been published for outside review, the normal process for vetting new medical research.

Top U.S. health officials continue to stress that vaccination will remain the best way to protect against infection. But with tens of millions of adults still unvaccinated — and many more globally — effective, easy-to-use treatments will be critical to curbing future waves of infections.

The FDA has set a public meeting later this month to review Merck’s pill, known as molnupiravir. The company reported in September that its drug cut rates of hospitalization and death by 50%. Experts warn against comparing preliminary results because of differences in studies.

Although Merck’s pill is further along in the U.S. regulatory process, Pfizer’s drug could benefit from a safety profile that is more familiar to regulators with fewer red flags. While pregnant women were excluded from the Merck trial due to a potential risk of birth defects, Pfizer’s drug did not have any similar restrictions. The Merck drug works by interfering with the coronavirus’ genetic code, a novel approach to disrupting the virus.

Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.

The drug, which has not yet been named, was first identified during the SARS outbreak originating in Asia during 2003. Last year, company researchers decided to revive the medication and study it for COVID-19, given the similarities between the two coronaviruses.

The U.S. has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they have to be given by IV or injection at hospitals or clinics, and limited supplies were strained by the last surge of the delta variant.

Shares of Pfizer spiked more than 9% before the opening bell Friday.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

KSL 5 TV Live

Top Stories

Coronavirus

FILE: Pfizer-BioNTech COVID-19 (left) and Moderna COVID-19 (right) vaccines are seen at a vaccinati...
LOLITA C. BALDOR and KEVIN FREKING, Associated Press

Congress set to rescind COVID-19 vaccine mandate for troops

The COVID-19 vaccine mandate for members of the U.S. military would be rescinded under the annual defense bill heading for a vote this week in Congress.
2 days ago
Epidemic control workers wear PPE to protect against the spread of COVID-19 while guarding the gate...
Joe McDonald, Associated Press

China eases anti-COVID measures following protests

China has rolled back rules on isolating people with COVID-19 and dropped virus test requirements for some public places.
2 days ago
2022 FLU SHOT...
Brenda Goodman, CNN

2022 Flu vaccine appears to be a very good match, CDC says

(CNN) — This year’s flu shot appears to be “a very good match” to the circulating strains, US Centers for Disease Control and Prevention Director Dr. Rochelle Walensky said at a news briefing Monday. However, she noted that flu vaccinations are lagging behind the pace of previous years. Through the end of October, CDC data showed […]
3 days ago
A healthcare worker prepares a dose of Pfizer-BioNTech Covid-19 vaccine at a vaccination site in Sa...
LAURAN NEERGAARD, AP Medical Writer

Pfizer asks FDA to clear updated COVID shot for kids under 5

Pfizer is asking U.S. regulators to authorize its updated COVID-19 vaccine for children under age 5.
4 days ago
FILE: U.S. Secretary of Defense Lloyd Austin speaks during a news briefing at the Pentagon July 21,...
TARA COPP, Associated Press

Keep COVID military vaccine mandate, defense chief says

Defense Secretary Lloyd Austin is making clear he wants to keep the military’s COVID-19 vaccine mandate in place to protect the health of the troops.
6 days ago
flu shot tripledemic...
Matt Rascon

KSL+: The rise of respiratory viruses and COVID’s impact

It’s not even winter yet, and the CDC is warning that the country is experiencing a resurgence of respiratory viruses, which are taking a toll on hospitals and children.
7 days ago

Sponsored Articles

notebook with password notes highlighted...
PC Laptops

How to Create Strong Passwords You Can Actually Remember

Learn how you can create strong passwords that are actually easy to remember! In a short time you can create new ones in seconds.
house with for rent sign posted...
Chase Harrington, president and COO of Entrata

Top 5 reasons you may want to consider apartment life over owning a home

There are many benefits of renting that can be overshadowed by the allure of buying a home. Here are five reasons why renting might be right for you.
Festive kitchen in Christmas decorations. Christmas dining room....
Lighting Design

6 Holiday Decor Trends to Try in 2022

We've rounded out the top 6 holiday decor trends for 2022 so you can be ahead of the game before you start shopping. 
Happy diverse college or university students are having fun on their graduation day...
BYU MBA at the Marriott School of Business

How to choose what MBA program is right for you: Take this quiz before you apply!

Wondering what MBA program is right for you? Take this quiz before you apply to see if it will help you meet your goals.
Diverse Group of Energetic Professionals Team Meeting in Modern Office: Brainstorming IT Programmer...
Les Olson

Don’t let a ransomware attack get you down | Protect your workplace today with cyber insurance

Business owners and operators should be on guard to protect their workplace. Cyber insurance can protect you from online attacks.
Hand turning a thermostat knob to increase savings by decreasing energy consumption. Composite imag...
Lighting Design

5 Lighting Tips to Save Energy and Money in Your Home

Advances in lighting technology make it easier to use smart features to cut costs. Read for tips to save energy by using different lighting strategies in your home.
Pfizer says COVID-19 pill cut hospital, death risk by 90%